All posts by medical

Researchers Get First-Ever Look at a Rare but Vital Stem Cell in Humans – Technology Networks

Neutrophils are the warriors of the immune system. They are always ready to spring to action to help heal injuries or fight off disease. Unless, that is, something goes wrong in their developmental process.Immature neutrophils arent all warriors they can be dangerous turncoats. High levels of immature neutrophils in the bloodstream can be a tell-tale sign of cancer and may even be a biomarker for COVID-19.

Now scientists at La Jolla Institute for Immunology (LJI) have tracked down the rare stem cells that generate neutrophils in human bone marrow. This research, published in Immunity, gives researchers a potential path for intervening in diseases where neutrophil development goes awry.

We have identified the stem cells that are the early origins of neutrophils, the most abundant blood cell type in humans, says Huy Dinh, Ph.D., a former LJI postdoctoral associate who recently moved to a faculty position at The University of WisconsinMadison. Dinh led the study with LJI Professor Catherine C. Hedrick, Ph.D. Knowing how human neutrophils develop is especially relevant today because immature neutrophils have been found to be elevated in both the blood and lungs of severe COVID-19 patients.

Despite their importance, neutrophils have proven very hard to study. They dont hold up well outside the body, and the stem cells that make them are even harder to investigate because they only live in bone marrow.

In 2018, the Hedrick Lab reported the discovery of a group of progenitor stem cells that give rise to mature neutrophils. These progenitors sole job was to generate neutrophils, yet they appeared to also promote tumor growth. The researchers believed that detecting these progenitors could give doctors a better way to catch early cancer cases. But first, the team needed to know a lot more about neutrophil development.

The new research revealed a progenitor cell type that exists even earlier in human neutrophil development. Dinh, a past SPARK Award recipient, together with Tobias Eggert, Ph.D., a LJI visiting scientist and Melissa Meyer, Ph.D., a LJI postdoc, who served as the co-first authors in the study, spearheaded the effort to use a tool called cytometry by time-of-flight (CyTOF) to distinguish these rare cells from other types of immune progenitor cells. This work also made it possible for the researchers to identify more specific protein markers on this early progenitor cell surface.

The discovery of these protein markers was important because until now, scientists have used only a few of markers to track neutrophils over time. The new study gives scientists specific markers for tracking neutrophil development from day one.

The researchers also found that cases of skin and lung cancers are often accompanied by a flood of immature neutrophils including the early progenitor cells into the bloodstream. These immature neutrophils change as they interact with tumor cells, though the researchers arent sure yet how these changes affect cancer progression.

Dinh likens the stages of neutrophil development to the cars on a train. The early progenitors are like the train engine, keeping everything going smoothly along the track to maturity. Cancer shakes everything up, and immature neutrophils jump off the track before they reach maturity. Its like the train is falling apart, Dinh says.

Neutrophil development has been in the news recently due to the COVID-19 pandemic, as studies have shown immature neutrophils are also more abundant in some patients with COVID-19. Dinh and Hedrick think perhaps the threat of the virus prompts the body to churn out neutrophils too quickly, again forcing immature cells off the track to maturity.

We need to study this phenomenon further to see if these neutrophils can be tied to case prognosis or if they can be a drug target for COVID-19, says Dinh.

The researchers hope to continue their work to discover the exact mechanisms that stop neutrophils from reaching maturity. Knowing the earliest cell that gives rise to neutrophils is really critical for trying to target and control these cells, says Hedrick. But we dont know exactly how to do that yet.

This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.

Read the original post:
Researchers Get First-Ever Look at a Rare but Vital Stem Cell in Humans - Technology Networks

Immunology Professor Paul Moynagh says hes perplexed by Government decision putting sport behind closed doo – The Irish Sun

IMMUNOLOGY Professor Paul Moynagh says he's 'perplexed' by the Government's decision to put sport behind closed doors.

He cannot understand why it's being limited so much when it's been established that outdoor activity is far less risky than indoors.

2

2

He told RTE: "I'm probably perplexed actually with some of the decisions.

"I like to see decisions based on an evidence base and it seems like putting sport behind closed doors again and 200 spectators not being able to attend, that doesn't make sense to me.

"We know how this virus is transmitted.

"The risk of it being transmitted outdoors is significantly less than inside."

Taoiseach Micheal Martin this evening announced that all sport would go behind closed doors until September 13 at the earliest.

Acting CMO Ronan Glynn identified the gathering of people before and after matches as being the primary concern rather than during the matches themselves.

Most read in Football

TASTE OF VICTORYSligo Rovers player mocks John Sheridan after goal with pint gesture

Pictured

GEOR DROPPINGGeorgina Rodriguez shows off incredible figure while on yacht with Ronaldo

KO-EMANNext Barca president has already decided to axe Koeman... and replace him with Xavi

Revealed

GLOVE STORYMan Utd wages revealed with Henderson set to take home same amount as Bruno

MARC MY WORDSMan Utd set to confirm Marc Jurado as Barca kid comments on Fernandes' post

Exclusive

pot luckGambler trousers 100k after cashing out moments before he would have lost it all

With the GAA and League of Ireland already feeling the weight of massively crippling financial implications from having to restart with fewer than 200 fans in attendance over the last few weeks, today has come as an even bigger blow.

In fact, the GAA have requested an urgent meeting with Dr Glynn and NPHET in order to be shown empirical evidence that their matches have contributed to the spread of the disease.

The move has also generated a lot of chatter online with frustrated reactions coming from leading sporting figures such as TJ Reid and Des Cahill.

See original here:
Immunology Professor Paul Moynagh says hes perplexed by Government decision putting sport behind closed doo - The Irish Sun

Global Immunology Drug Market to Witness Heightened Growth During the Period 2017 2025 – Lake Shore Gazette

The immune system is an assembly of structures and processes inside the body to protect against possibly damaging foreign bodies and diseases. It identifies various threats like bacteria, viruses, and parasites and distinguishes them from bodys healthy tissues. When the immune system weakness and lose the capability to detect and destroy the abnormal cells or body attacks and damages its tissues lead to diseases like cancer and autoimmune diseases. Immunotherapy is a process which includes the treatment by inducing, enhancing or suppressing an immune system to fight against the diseases.

According to American Autoimmune Related Diseases Association, autoimmune disease affects up to 50 million Americans. Autoimmune diseases are of 80 types out of which most prevalent are rheumatoid arthritis, Systemic Lupus Erythematous (Lupus),Juvenile rheumatoid arthritis,inflammatory bowel arthritis, Psoriatic arthritis and affects different body organs like joints, muscles, skin, red blood cells, blood vessels, connective tissues and endocrine glands. Immunology drug is becoming the choice of several oncologists as they provide long-lasting affect by activating the immune system to identify cancerous cell and kill them through the natural process as well as improve the quality of survival. Some of the cancer treatment vaccines approved by FDA are bacillus Calmette-Gurin (BCG), Sipuleucel-T which propel the growth of the Immunology Drug market.

To remain ahead of your competitors, request for a sample here@ https://www.persistencemarketresearch.com/samples/15259

Immunology Drug Market: Drivers and Restraints

The increase in the prevalence rate of the different type of cancer and rheumatoid cancer, rising government initiatives, increasing funding from the various government and non-government organization is driving the immunology drug market. Patients with poor prognosis are expected to drive the growth of the immunology drugtrial evidence reveals that after preparing the immune system to fight against cancer immunology, drug effects last for a long time even after the reduction of the tumor. High costs of immunology drug and lack of awareness could be the possible restraints for the immunology drug market. Also, the introduction of generic drugs in some regions and slower pipeline development are the challenges for the immunology drug market.

Immunology Drug Market: Segmentation

Immunology drug market is segmented by drug class and the end users.

To the date most clinically and effective drugs in monoclonal antibodies are Humira (adalimumab) and Remicade (infliximab).

To receive Methodology request here @ https://www.persistencemarketresearch.com/methodology/15259

Immunology Drug Market: Overview

Development of some new drugs with success rate is expected to offer the good opportunity for immunology drug market. Wide-ranging scope of Immuno-oncology agents in different cancer treatments would provide the maximum share to immunology drug market in the forecast period. pharmaceutical companies and R&D are showing increased interest in this field and is expected to offer better potential for immunology drug market. Companies involved in partnership and R&D for efficient technologies are some of the latest trends that have been observed in immunology drug market. Currently, most of the immunology drugs are in clinical trial and are expected to rise the immunology market after clearance or success of these products from clinical trials.

Immunology Drug Market: Region-wise Outlook

North America has the largest share globally in immunology drug market because of the availability of better reimbursement policies, high potential to invest the huge amount of money in the development of immunology drug and the advancement in the technologies. Europe is the second largest region regarding value because of the easy accessibility to the immunology drug, and also the affordability for the cost of treatment is high. Increase in awareness, rising economy, increasing government initiatives and large patient pool in Asia-Pacific regions also demonstrates the higher growth in Immunology Drug Market.

To receive extensive list of important regions, Request TOC here @ https://www.persistencemarketresearch.com/toc/15259

Immunology Drug Market: Key Market Participants

Some of the major players in Immunology drug market are

The research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry-validated market data. It also contains projections using a suitable set of assumptions and methodologies. The research report provides analysis and information according to market segments such as geographies, application, and industry.

See the original post:
Global Immunology Drug Market to Witness Heightened Growth During the Period 2017 2025 - Lake Shore Gazette

Qu Biologics Initiates Phase 2 Study to Assess Activation of Anti-cancer Immune Response in Colon Cancer – Up News Info

VANCOUVER, British Columbia, Aug. 18, 2020 (GLOBE NEWSWIRE) Qu Biologics Inc., a biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a novel platform of immunotherapies designed to restore innate immune function, is pleased to announce approval from the Israeli Ministry of Health to proceed with their clinical trial of QBECO SSI in patients with colorectal cancer. The study, Assessment of QBECO SSI on Immunological Parameters in the Tumor Microenvironment and Systemically in Patients with Colorectal Cancer will enroll patients at the Sheba Medical Center with Principal Investigator Dr. Gal Markel.

Professor Markel, a medical oncologist, is an internationally recognized expert in translational tumor immunology and clinical immuno-oncology. Professor Markel is Associate Professor in Clinical Microbiology and Immunology at the Sackler School of Medicine at Tel Aviv University and Director of the Ella Lemelbaum Institute for Immuno-Oncology. We are delighted to have the opportunity to work with Qu Biologics, and their innovative technology, which has the potential to induce immunological impact in colon cancer patients, stated Professor Markel.

The study is designed to assess the effect of QBECO SSI treatment on immune function in the tumor and systemically in patients newly diagnosed with colon cancer. Colorectal cancer suppresses the patients immune response. This immune suppression is recognized to have a detrimental effect on prognosis. In the study, participants will receive QBECO SSI treatment from the time of colon cancer diagnosis to the time the tumor is surgically removed 3-5 week later. Preclinical studies using cancer models in mice have demonstrated that Qus SSIs substantially enhance immune function both in the tumor and systemically, resulting in tumor reduction and improved survival. Hal Gunn, CEO of Qu Biologics, stated, We are very pleased to be able to work with Dr. Markel, the Ella Lemelbaum Institute for Immuno-Oncology, and the Sheba Medical Centre on this important clinical study. The perioperative period presents a window of opportunity to activate immune function in this patient population to overcome cancer-induced immune suppression and improve prognosis. If positive, the results could have transformative potential in colon cancer therapy. Qus Director of Scientific Innovation, immunologist Dr. Shirin Kalyan, added, It has long been recognized that activating innate anti-cancer mechanisms in this manner could lead to tumor regression. We just have not had the right treatment approaches to elicit this response safely and consistently before. We are hopeful that Qus SSIs can provide this. The results of this study are anticipated in Q2 2021.

Qu has published the basis of their innate immune therapy as well as the mechanism by which it activates anti-cancer immunity.

Qu Biologics and Dr. Markel would like to thank the Samueli Foundation for its generous support of this important study that made this research possible.

For more information about Qu Biologics and the science behind SSIs, please visit http://www.qubiologics.com.

About Qu BiologicsQu Biologics is a clinical stage biotechnology company developing Site Specific Immunomodulators (SSI), a novel class of immunotherapies designed to stimulate an innate immune response in targeted organs to reverse the chronic inflammation underlying many important diseases including inflammatory bowel disease, cancer, inflammatory lung disease and arthritis. Qu has completed three Phase 2 studies in Crohns disease, ulcerative colitis and lung cancer.

Backed by a prestigious group of scientific advisors and board members, Qu Biologics is led by a management team that includes co-founder and CEO Dr. Hal Gunn, a physician and expert on the bodys immune response to chronic disease; and Chief Medical Officer Dr. Simon Sutcliffe, former CEO of the BC Cancer Agency and a distinguished clinician, scientist and leader in cancer control in Canada and internationally.

For more information regarding this press release, contact:

Hal Gunn, MDCEOQu Biologics Inc.Phone: 604.734.1450 Email: [emailprotected]

Qu Biologics Inc. cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. Forward-looking statements are only predictions based upon current expectations and involve known and unknown risks and uncertainties. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of release of the relevant information, unless explicitly stated otherwise. Actual results, performance or achievement could differ materially from those expressed in, or implied by, Qu Biologics forward-looking statements due to the risks and uncertainties inherent in Qu Biologics business including, without limitation, statements about: the progress and timing of its clinical trials; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing its products; unexpected adverse side effects or inadequate therapeutic efficacy of its products that could delay or prevent product development or commercialization; the scope and validity of patent protection for its products; competition from other pharmaceutical or biotechnology companies; and its ability to obtain additional financing to support its operations. Qu Biologics does not assume any obligation to update any forward-looking statements except as required by law.

Read more here:
Qu Biologics Initiates Phase 2 Study to Assess Activation of Anti-cancer Immune Response in Colon Cancer - Up News Info

Regeneration of vascular cells is regulated by RNA-binding protein – News-Medical.net

Through their basic research, physicians at the Heart Center of the University Hospital Bonn have discovered how the communication between individual cells can be influenced with the help of a specific protein.

These findings are an important approach to improving the treatment of diseases such as arteriosclerosis (calcified blood vessels), which causes heart attacks. The study was published online in advance in the Journal of Extracellular Vesicles, the printed version will be published shortly.

The human body consists of an inconceivably large number of cells. Current scientific studies assume around 40 trillion cells, depending on the weight and size of the person.

Most cells come together to perform their function in the body in the best possible way. Collectively they form tissue, organs and muscles. The most important requirement for good cellular interaction is for the cells to communicate with each other as effectively as possible.

In order for cells to communicate effectively with each other, they need a postman to carry information from one cell to the next. This is precisely the role played by extracellular vesicles."

Dr Andreas Zietzer, Cardiologist, Heart Center, Bonn University Hospital

For a long time, these vesicles were considered to have little biological significance. It was assumed that the vesicles were only used to get rid of excess proteins and other molecules, making them a kind of cellular garbage disposal. However, it is now known that vesicles play a key role in intercellular communication.

The principle of the vesicles can be explained quite simply: They are released as extremely small membrane bubbles - only about two thousandths of a millimeter in size - by cells in our body and can then be taken up and utilized by other cells.

Zietzer describes the crucial function of the vesicles "as postmen, they transport various contents and thereby enable the exchange of information between cells."

In addition to proteins and lipids, this communication process also involves transporting ribonucleic acids (RNAs). These RNAs are copies of the genetic information and are required for carrying out its function.

The physicians at the University of Bonn concentrated their research primarily on so-called microRNAs, which are responsible for fine tuning the switching on and off of genes.

"Because microRNAs have considerable influence on the biology of the cells, vesicles can influence the function of recipient cells depending on their specific cargo," says Zietzer.

This is because, depending on which microRNA is enriched in the vesicles, the information transported by the vesicles also changes and with it the effect on the recipient cells that take up the vesicles and their cargo.

"It would be a breakthrough for researchers and physicians if they could control which information is transported between cells and which is not," says Zietzer, looking to the future. "However, precisely this kind of manipulation of cell-to-cell communication has so far been barely investigated."

The research group, led by Dr. Andreas Zietzer, Dr. Rabiul Hosen and Dr. Felix Jansen (head of the research group), at the Heart Center of the University Hospital Bonn has now succeeded in using a new mechanism on human cells to clarify how the sorting of specific RNAs within the vesicles works.

To this end, the researchers used a mass spectrometer to identify more than 3,000 proteins and 300 microRNAs that were found to be enclosed in the vesicles and ready for transport to other cells.

The three researchers were able to show that a specific RNA-binding protein (hnRNPU for short) retains the microRNAs in the donor cell like a sponge, thereby preventing them from being packed into vesicles and transported to another cell.

The exact opposite is true when this particular protein is switched off: In this case there is an elevated release of the microRNAs, which are then increasingly packed into the vesicles.

"The RNA-binding protein hnRNPU therefore assumes the role of a gatekeeper, deciding which and how many microRNAs are released from the donor cell for transport to the recipient cell," Andreas Zietzer summarizes the research results. This function enables the protein hnRNPU to significantly influence the communication between cells.

These observations hold great therapeutic potential; Zietzer, Hosen and Jansen were able to show that the transfer of certain microRNAs via the vesicles can be controlled by increasing or reducing the amount of hnRNPU in the donor cells.

"This enables a targeted release, or retention, of microRNAs that promote regeneration and thereby positively or negatively influence the regenerative ability of diseased vascular cells," comments Zietzer on the potential intervention in cellular communication.

Medically, this is of high importance, as the regenerative ability of the vascular cells in calcified vessels (arteriosclerosis) is already limited in the early stages of the disease.

Zietzer, Hosen, and Jansen now hope to apply their findings on intercellular communication using extracellular vesicles: "It is, for instance, conceivable that the targeted local activation or deactivation of the protein hnRNPU in healthy parts of the vascular system might lead to a 'swarm' of regeneration-promoting vesicles to be dispatched, which could then be taken up by already damaged vascular areas and accelerate regeneration there. In critical situations, such as after a heart attack, this could promote the healing process of patients," says Zietzer about the concrete benefit of this basic research.

Further applicability studies are in progress. The current research results suggest that this mechanism is also of great importance in the progression of heart and kidney diseases.

The costs for this research of approximately 300,000 euros were provided by the German Research Foundation, the German Cardiac Society, the Corona Foundation, and the Faculty of Medicine of the University of Bonn.

Source:

Journal reference:

Zietzer, A., et al. (2020) The RNA-binding protein hnRNPU regulates the sorting of microRNA-30c-5p into large extracellular vesicles. Journal of Extracellular Vesicles. doi.org/10.1080/20013078.2020.1786967.

Continue reading here:
Regeneration of vascular cells is regulated by RNA-binding protein - News-Medical.net

‘From the Valley, For the Valley’: Local Students Start Training at UCSF to Become Physicians for the Region | Newsroom – UC Merced University News

The San Joaquin Valley has a shortage of doctors, but students such as Kyle Shen (18) aim to change that by attending a tailored track at UCSFs medical school specifically designed to address this problem.

Shen is one of 12 recently admitted to the newest cohort of students in the UCSF San Joaquin Valley Program in Medical Education, or SJV PRIME. SJV PRIME is for medical students who are committed to ensuring high-quality, culturally appropriate, and accessible medical care to improve health for individuals and communities in the Valley.

I care very much about my hometown, and this program aligns with what I would like to achieve in the future,said Shen, who graduated from UC Merced with a degree in biological sciences with an emphasis in molecular and cell biology. Starting this fall has its challenges because of COVID-19, but Im excited to finally start medical school.

A Merced native, Shen saw first-hand how the physician shortage affected his friends and family, which spurred his interest in pursuing medicine. He volunteered in a local hospitals intensive care unit in high school and college and plans to practice medicine in Merced upon the completion of his program.

Besides bringing more doctors to the Valley, SJV PRIMEs goals include diversifying the workforce with people who understand the communities they are serving. Fifty percent of SJV PRIME students come from backgrounds underrepresented in medicine and 42 percent are the first in their families to graduate from college.

The Valley has one of the lowest ratios of practicing doctors in California and the COVID-19 pandemic underscores the need for more physicians, physician leaders and physician change makers in the region, especially those who come from the diverse communities they serve.

As part of their introduction to the program, incoming students participate in ARISE, or Advance Regional Information: Summer Education. ARISE exposes students to various activities with community partners and initiatives to address health disparities and research unique to the Valley. Community participants include the Fresno County Health Improvement Partnership, Black Infant Mortality Group, Merced-based health educational center Healthy House and local physicians, among others. While ARISE took place virtually due to COVID-19, students were still able to connect with UC Merced faculty and learn about health-related research.

The SJV PRIME Matriculating Class of 2020 is composed of students from a range of Valley towns, including Fresno, Selma, Clovis, Turlock, Merced, Fowler, Reedley and Patterson.

SJV PRIME represents the sixth program in the University of Californias Programs in Medical Education. It was established in 2010 as a partnership among the UC Davis School of Medicine, UC Merced, UCSF Fresno and the UCSF School of Medicine.

Find out more about SJV PRIME here.

Read more here:
'From the Valley, For the Valley': Local Students Start Training at UCSF to Become Physicians for the Region | Newsroom - UC Merced University News

OU professor awarded $550,178 grant by National Science Foundation – College of Arts and Sciences – 2020 – News – OU Magazine – News at OU

Oakland University Professor Luis Villa-Diaz has been awarded a $550,178 grant by the National Science Foundation (NSF) for his research on stem cell biology and the potential use of stem cells in regenerative medicine.

Stem cells are cells with the unique ability to divide into identical daughter cells or to differentiate into specialized cell types, said Villa-Diaz, an assistant professor in the biological sciences and bioengineering departments at Oakland University. A better understanding of stem cell biology will advance knowledge of how organs and tissues are formed and maintained during the life of an organism, as stem cells are responsible for those functions.

Villa-Diaz will serve as the principle investigator on the project, which will examine the biological mechanisms that stem cells use to perform two of their main characteristics, including the capacity to divide and create an identical daughter cell a process known as self-renewal and the potential for stem cells to change their identity and become a specialized, differentiated cell.

My lab has been investigating for years these properties and new molecular pathways that are involved on both biological processes, he said. In this project, we will determine the potential function of two proteins the Focal Adhesion Kinase (FAK) and Integrin-Linked Kinase (ILK) in the nuclei of stem cells regulating the degradation of proteins involved in the regulation of genes that induce stem cell differentiation.

These roles might be unique for stem cells, as in somatic cells these proteins play other roles, Villa-Diaz added. Confirming these new activities of these proteins in the nuclei of stem cells will impact our knowledge of stem cell biology and will help us to better use these cells for therapeutic use in regenerative medicine.

In addition, this project will provide training opportunities for two new graduate students and multiple undergraduates, who will be directly involved in the research activities of this project. Dozens of graduate students will also be trained in methods to effectively communicate scientific knowledge to the public as an outreach component of the NSF grant.

This NSF award means a lot to me because it is a vote of trust on my research program, Villa-Diaz said.

Read the original post:
OU professor awarded $550,178 grant by National Science Foundation - College of Arts and Sciences - 2020 - News - OU Magazine - News at OU

HI’s Dr. Sergio Gradilone invited to join NIH study section – Austin Daily Herald – Austin Herald

Dr. Sergio Gradilone, senior faculty member of The Hormel Institute, University of Minnesota, earned an invite to serve as a member of the National Institutes of Health (NIH) Hepatobiliary Pathophysiology Study Section. These critically important study sections review grant applications for specialized research. Gradilone will serve for a term of six years.

Dr. Sergio Gradilone

It was a great honor to receive this nomination by NIH officials and then the letter from UMN Vice President Chris Cramer acknowledging the position, Gradilone said. For me it is exciting to serve in this capacity and is win-win. I will help examine and review potential and innovative research projects which make an impact on cancer research and liver diseases in general, and share what Ive learned about the particular cancer research areas weve been dedicated to.

Gradilone leads the Cancer Cell Biology & Translational Research lab at The Hormel Institute and his research focuses on how a normal cell becomes a cancerous one, looking specifically at the primary cilium, a part of a cell similar to an antenna that receives signals from the environment around it. Gradilones research is currently directed at an aggressive form of liver cancer called cholangiocarcinoma, which originates in the epithelial cells of the bile ducts.

The Hepatobiliary Pathophysiology Study Section reviews grant applications for research involving diseases of the liver, gallbladder, bile ducts or bile. While the study section looks at a wide range of diseases, Gradilone will bring his cancer expertise to the group.

The NIH is a major government source of research grants and all applications go through the NIHs Center for Scientific Review. To make sure each application is properly vetted, there are study sections made up of experts in their respective fields who review those applications.

Study section members are selected based on their publishing record, participation in major scientific meetings, grant funding, and overall recognition of expertise within the field. Members give a significant amount of professional time to their duties and perform an important function in the grant process for biomedical research.

Examples of grant review panels Institute faculty have served on:

American Cancer Society Peer Review Committee on Carcinogenesis, Nutrition, and the Environment

LOreal USA Fellowships For Women in Science

National Science Foundation

NIH Tumor Cell Biology study section

American Cancer Society Institutional Research Grants

Cancer Research UK international

Read more here:
HI's Dr. Sergio Gradilone invited to join NIH study section - Austin Daily Herald - Austin Herald

3D Cell Cultures: Technologies and Global Markets to 2025 Featuring Agilent Technologies, BioVision, Cell Applications, Envisiontec, Mitra Biotech,…

DUBLIN--(BUSINESS WIRE)--The "3D Cell Cultures: Technologies and Global Markets" report has been added to ResearchAndMarkets.com's offering.

The report includes:

Whether the discussion is about stem cells, tissue engineering, or microphysiological systems, their vital role in drug discovery, toxicology, and other areas leading to new product development, 3D cell culture is becoming the environment that will increasingly define the basis for future advances.

To mix metaphors, 3D cell culture is also cross-roads through which just about everything else passes on its way to building knowledgebases or introducing new products. This study is needed to bring together and make sense out of the broad body of information encompassed by 3D cell culture.

Three-dimensional cell culture has been used by researchers for many years now, with early adoption and now key roles in cancer and stem cells. Organ-on-a-chip technology, also known as microphysiological systems, is leading to dramatic breakthroughs. Also, stem cell research coupled with synthetic biology is opening new areas. This study is needed to provide a perspective on these advances.

Furthermore, classical toxicology testing programs have been in place for many decades, and over the past 20 years, animal welfare and scientific activities have spurred the development of in vitro testing methods. In silico methods are advancing in novel ways that need to be analyzed and considered in terms of their impacts on cell culture.

This report investigates the recent key technical advances in 3D cell culture equipment, raw materials, assay kits, analytical methods, and clinical research organization (CRO) services. It should also be pointed out that this report takes a somewhat different position on 2D cell culture. It has been criticized for its inadequacies and the misleading information it can produce. However, a review of industry practices makes it clear that it still has its place and will contribute to future advances in unexpected ways.

The company section looks at many of the suppliers who provide equipment, assays, cells, reagents, and services used in 3D cell culture. This study sought to understand business models and market maturity dynamics in greater depth as well as providing more quantitative analysis of their operations.

Key Topics Covered

Chapter 1 Introduction

Chapter 2 Summary

Chapter 3 Highlights and Issues

Chapter 4 Tissue and Cell Culture: Technology and Product Background

Chapter 5 Assays, Imaging and Analysis

Chapter 6 Regulation and Standardization

Chapter 7 3D Models for Cancer

Chapter 8 Landscape for Toxicology and Drug Safety Testing

Chapter 9 Stem Cell Landscape

Chapter 10 Regenerative Medicine: Organ Transplants and Skin Substitutes

Chapter 11 Company Profiles

For more information about this report visit https://www.researchandmarkets.com/r/htgg5z

More:
3D Cell Cultures: Technologies and Global Markets to 2025 Featuring Agilent Technologies, BioVision, Cell Applications, Envisiontec, Mitra Biotech,...

Life Science Tools and Reagents Market Is Estimated to Over the Forecast Period Key Players are: Abbott Laboratories, Abcam, BD Biosciences, Beckman…

The report provides a unique tool for evaluating the Market, highlighting opportunities, and supporting strategic and tactical decision-making. This report recognizes that in this rapidly-evolving and competitive environment, up-to-date marketing information is essential to monitor performance and make critical decisions for growth and profitability. It provides information on trends and developments, and focuses on markets capacities and on the changing structure of the Life Science Tools & Reagents.

Get Sample Copy of The Report NOW!

https://www.marketinsightsreports.com/reports/08132211052/global-life-science-tools-reagents-market-insights-and-forecast-to-2026/inquiry?Mode=21

Top leading Manufactures Profiled in Life Science Tools & Reagents Market Report are:

Abbott Laboratories, Abcam, BD Biosciences, Beckman Coulter Inc., Benitec, Bio-Rad Laboratories, Cell Sciences, Cell Signaling Technology, Cepheid Inc., Charles River Laboratories International Inc., Echelon Biosciences Inc., Emd Millipore, Enzo Biochem, High Throughput Genomics Inc., Illumina Inc., Lifesensors Inc., Lonza Group AG, Luminex Corp., Stemgent, Sysmex-Partec Gmbh, Thermo Fisher Scientific Inc., Trilink Biotechnologies, Tocris Bioscience (Bio-Techne), Vitro Diagnostics Inc., Waters Corp., Xenotech Llc

Market Research Study Focus on these Types:

Tools

Reagents

Market Research Study Focus on these Applications:Proteomics

Cell biology research

Epigenetics

Metabolomics

Bioinformatics

Others

Inquire for Discount of Life Science Tools & Reagents Market Report at:

https://www.marketinsightsreports.com/reports/08132211052/global-life-science-tools-reagents-market-insights-and-forecast-to-2026/discount?Mode=21

Life Science Tools & Reagents Market Scenario:

This research report represents a 360-degree overview of the competitive landscape of the Life Science Tools & Reagents Market. Furthermore, it offers massive data relating to recent trends, technical advancements, tools, and methodologies. The research report analyzes the Life Science Tools & Reagents Market in a detailed and concise manner for better insights into the businesses.

Furthermore, this report on the Life Science Tools & Reagents market demonstrates the recent trends, financial opportunities, governing policies, industry share, manufacturing status of the Life Science Tools & Reagents market, supply chain structure, marketing dynamics and competitive landscape and so on.

Table of Contents:

-Life Science Tools & Reagents Market Overview

-Economic Impact on Industry

-Market Competition by Manufacturers

-Production, Revenue (Value) by Region

-Supply (Production), Consumption, Export, Import by Regions

-Production, Revenue (Value), Price Trend by Type

-Market Analysis by Application

-Manufacturing Cost Analysis

-Industrial Chain, Sourcing Strategy and Downstream Buyers

-Marketing Strategy Analysis, Distributors/Traders

-Market Effect Factors Analysis

-Life Science Tools & Reagents Market Forecast

In conclusion, Life Science Tools & Reagents market report presents the descriptive analysis of the parent market supported elite players, present, past and artistic movement information which is able to function a profitable guide for all the Life Science Tools & Reagents Industry business competitors. Our expert research analysts team has been trained to provide in-depth market research report from every individual sector which will be helpful to understand the industry data in the most precise way.

How we have factored the effect of Covid-19 in our report:

All the reports that we list have been tracking the impact of COVID-19 the market. Both upstream and downstream of the entire supply chain has been accounted for while doing this. Also, where possible, we will provide an additional COVID-19 update supplement/report to the report in Q3, please check for with the sales team.

Contact US:

Irfan Tamboli (Head of Sales) Market Insights Reports

Phone:+ 1704 266 3234

Mob:+91-750-707-8687

[emailprotected]

[emailprotected]

More:
Life Science Tools and Reagents Market Is Estimated to Over the Forecast Period Key Players are: Abbott Laboratories, Abcam, BD Biosciences, Beckman...